Table 2.

Multivariable analysis for the Metastatic Assay validation in the radiation biopsy cohort for biochemical failure-free survival (left) and metastasis-free survival (right)

Biochemical failure-free survival (BFFS)				Metastatic-free survival (MFS)
Covariate	HR	95% CI	P	Covariate	HR	95% CI	P
Multivariate model 1				Multivariate model 1
Metastatic Assay (negativea versus positive)	1.94	1.13 to 3.31	0.0163	Metastatic Assay (negativea versus positive)	2.71	1.11–6.63	0.0300
Gleason: (a3+4)				Gleason: (a3+4)
6	0.66	0.25–1.74	0.3506	6	0.57	0.06–5.46	0.6240
4+3	1.71	0.79–3.71	0.1290	4+3	2.34	0.55–10.03	0.2545
8–10	1.33	0.60–2.95	0.4290	8–10	3.13	0.71–13.88	0.1349
Age	0.96	0.93–1.00	0.0505	Age	0.99	0.93–1.05	0.7259
PSA	1.00	1.00–1.01	0.2430	PSA	1.01	1.00–1.02	0.0914
ADT (long coursea versus short course)	1.53	0.77–3.04	0.2304	ADT (long coursea versus short course)	3.01	0.99–9.15	0.0538
T-stage (1 and 2a versus 3 and 4)	1.62	0.86–3.03	0.1345	T-stage (1 and 2a versus 3 and 4)	1.91	0.58–6.30	0.2912
Multivariate model 2				Multivariate model 2
Metastatic Assay (negativea versus positive)	2.46	1.31–4.62	0.0051	Metastatic Assay (negativea versus positive)	3.23	1.22–8.59	0.0185
CAPRA (low riska versus high risk)	1.24	0.61–2.55	0.5499	CAPRA(low riska versus high risk)	1.88	0.52–6.77	0.3320

MVA model 1 includes adjustment for the following clinical factors, age, PSA, Gleason, T-stage and ADT (dichotomized by treatment group). MVA model 2 includes adjustment for the CAPRA tool. In all models, P-values, hazard ratios and 95% confidence intervals are indicated.

^aReference category.

HR, hazard ratio; CI, confidence intervals; PSA, prostate specific antigen; CAPRA, Cancer of the Prostate Risk Assessment; ADT, androgen deprivation therapy.